FUJIFILM Cellular Dynamics, Inc.
525 Science Drive
Madison, WI 53711 USA

Toll Free in US (877) 320-6688 / (608) 310-5100 **T**
(608) 310-5101 **F**
fcdi-support@fujifilm.com **E**
www.fujifilmcdi.com **W**

Biosafety Documentation:

iCell® DopaNeurons G2019S/G Mutation-corrected Control

Donor ID	11299	**Cell Line ID**	11299.1291
Donor Sex	Male	**Genotype**	LRRK2 G2019S/G
Starting Material	Blood	**Catalog #**	C1255, C1256
Age at Collection	40 - 50 years		
Race	Caucasian		
Ethnicity	Unknown		

Cell Source and Biosafety Level Classification

iCell® products are human cells differentiated from a master bank of stably induced pluripotent stem (iPS) cells. FUJIFILM Cellular Dynamics, Inc. (FCDI), classifies these cells as Biosafety Level 1 (BSL1) based on the United States Centers for Disease Control and Prevention publication: *Biosafety in Microbiological and Biomedical Laboratories*. Handle the cells according to the biosafety guidelines applicable in your region.

Reprogramming

The iPS cell line was generated from human peripheral blood through ectopic expression of reprogramming factors by episomal transfection.

Polymerase chain reaction analysis did not detect episomal plasmids in the iPS cell line.

Engineering

The iPS cells were engineered to express neomycin resistance under the control of a neuronal-specific promotor. A puromycin resistance cassette was also included in the targeting vectors to enable selection of the engineered iPS cell clones.

The resulting engineered iPSC line was further engineered to correct the LRRK2 G2019S heterozygous SNP to LRRK2 G2019G homozygous status. No additional drug selection cassettes were introduced.

None of the engineering vectors used contain oncogenes.

Infectious Disease Testing

The incoming peripheral blood was tested and non-reactive for HBV, HCV, HIV-1, and HIV-2.